Skip to content
Menu
Ranked #165

Medro

Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible.

Desk Score 71/100 (C) · Verified July 2026

Visit MedroAssume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way.

Is Medro legit?

Only what Medro publishes and what we could check ourselves — nothing inferred. See the methodology.

Certification
Medro publishes a LegitScript certification on its own pages.
Where it ships
All 50 states, as published on the site.
Last checked
July 2026, against Medro's own pages.
Published price
Medro publishes a figure for semaglutide and tirzepatide — the qualifiers are in "What does Medro cost?" below.
What it sells
Brand-name medication as well as compounded, injectable route only.
Licensing & trust
70/100 on the scored dimension of that name — one of the six in our published methodology.

Checks out on the facts we can verify: a flat month-to-month price, coverage published nationwide, and a dated check against the company's own pages.

What does Medro cost?

Each figure exactly as Medro publishes it, with the condition attached to it spelled out.

Semaglutide

$199/mo (compounded)

That is a flat month-to-month rate: $199 a month, with no plan term attached to the figure.

Median semaglutide figure across this site: $190 a month, of 164 providers with a published month-to-month price and a check date. Medro's $199 a month sits $9 above it.

Tirzepatide

$299/mo (compounded)

That is a flat month-to-month rate: $299 a month, with no plan term attached to the figure.

Median tirzepatide figure across this site: $264 a month, of 163 providers with a published month-to-month price and a check date. Medro's $299 a month sits $35 above it.

All figures as published on Medro's own site and read in July 2026. Prices change — confirm before you order.

Semaglutide
$199/mo
Tirzepatide
$299/mo
Coverage
All 50 states
Brand-name
Yes
Verification
Prices as published on Medro's site — verified july 2026. Each figure's full condition is in “What does Medro cost?” below.

Weigh Medro against the full ranked field on the best semaglutide providers ranking, or line it up against its closest alternatives. Or go one-on-one: Medro vs CoreAge Rx.

Desk Score breakdown

Each of the six scored dimensions. See the methodology.

Price transparency52/100
State access86/100
Molecule range79/100
Onboarding speed78/100
Support responsiveness64/100
Licensing & trust70/100

What we like

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where points come off

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.

The bottom line — C

Best for: Compounded or brand semaglutide/tirzepatide with transparent tiered pricing and no membership, all 50 states.

Medro ranks #165 of 542 providers scored — see #1, CoreAge Rx here.

Related reviews

Everyone else here (24)

Pricing and verification reflect Medro's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on Medro's site. Not medical advice; see our disclosure.

← Back to the ranking